New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For JNJ;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
11:31 EDTBMYLion Biotechnologies TIL combo data an 'important' positive, says Piper Jaffray
After Lion Biotechnologies (LBIO) announced the report of positive results from a pilot trial of tumor infiltrating lymphocytes, or TIL, in combination with Bristol-Myers' (BMY) Yervoy in patients with metastatic melanoma, Piper Jaffray noted that the success rate for receiving TIL combo treatment was significantly higher than the prior result for TIL monontherapy. Piper said this fact highlights the combo approach may drive significantly broader application of TIL than it initially expected and the firm reiterated its Overweight rating and $21 price target on Lion shares.
March 29, 2015
14:06 EDTJNJJ&J announces study findings of paliperidone palmitate published in JAMA
Subscribe for More Information
March 27, 2015
15:14 EDTJNJJohnson & Johnson not likely to buy Intuitive Surgical, says BofA/Merrill
Subscribe for More Information
09:59 EDTJNJJohnson & Johnson to collaborate with Google to advance surgical robots
Subscribe for More Information
06:46 EDTJNJContact lens makers, discounters battling over price setting, NY Times says
Subscribe for More Information
March 26, 2015
07:30 EDTBMYDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 25, 2015
07:29 EDTJNJLeerink to hold booth tours
Leerink Booth Tours at AAOS 2015 will be held in Las Vegas on March 25-26.
March 24, 2015
13:24 EDTJNJContact lens manufacturers accused of price-fixing, Bloomberg says
Subscribe for More Information
08:02 EDTBMYBristol-Myers acquires exclusive license from Novo Nordisk for research program
Subscribe for More Information
07:45 EDTJNJFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
March 23, 2015
09:03 EDTJNJLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 20, 2015
07:55 EDTBMYAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
March 17, 2015
05:35 EDTJNJJohnson & Johnson to invest $10M in UK government fund to fight dementia
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use